Jennifer A Woyach MD

Jennifer A Woyach MD
Asst ProfessorCollege of Medicinejennifer.woyach@osumc.eduwebsite
455A Wiseman Hall 410 W 12th Avenue Columbus OH 43210
  • Experimental Therapeutics

Research Description

Dr. Woyach’s research interests include chronic lymphocytic leukemia and other hematologic malignancies. Her laboratory research focuses on the role of Bruton’s Tyrosine Kinase (BTK) in the development and expansion of CLL as well as therapeutic BTK inhibition in CLL using murine and cellular models. She is also interested in resistance to BTK inhibitor therapy. Dr. Woyach’s clinical research is focused on novel agents in CLL, and I am the PI of two early phase clinical trials and the intergroup chair of a phase III trial in CLL that will be opening later this year.

Current Publications

  • Byrd JCProlonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.Blood 123 1810-7 3/20/2014
  • Johnson AJBruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).Blood 123 1207-13 2/20/2014
  • Byrd JCImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed Del(17p13.1) karyotype at a single center.Leukemia 1/23/2014
  • Lucas DM, Hertlein E, Lu Y, Sass EJ, Lapalombella RT, Chen TL, Davis M, , Lehman A, Jarjoura D, Byrd JCThe proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.Clin Cancer Res 19(9) 2406-19 5/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: